title: [Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].
abstract: Kidney plays a role in glucose homeostasis, not only by its capacity to produce glucose through local gluconeogenesis, but also, and even more important in presence of diabetes, by its capacity to excrete glucose in urine when hyperglycaemia exceeds tubular reabsorption threshold. Such reabsorption depends on sodium-glucose cotransporters-2 (SGLT2), which can be blocked by selective inhibitors. These pharmacological agents augment glucosuria and reduce hyperglycaemia independently of insulin. Some have already proven their efficacy to improve glucose control, in monotherapy or in combination, while promoting weight loss and without inducing hypoglycaemia. Dapagliflozin should be the first medication of this new pharmacological class to be commercialized for the management of type 2 diabetes.
authors.affiliation: Service de diabétologie, nutrition et maladies métaboliques, Département de médecine, CHU Sart-Tilman, Liège, Belgique. andre.scheen@chu.ulg.ac.be
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.forename: R P
authors.initials: RP
authors.lastname: Radermecker
authors.forename: P
authors.initials: P
authors.lastname: Ernest
authors.forename: B J
authors.initials: BJ
authors.lastname: Jandrain
mesh_terms: D001559:Benzhydryl Compounds; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005960:Glucosides / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D051247:Sodium-Glucose Transport Proteins / Q000037:antagonists & inhibitors*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D051247:Sodium-Glucose Transport Proteins; C529054:dapagliflozin